DOP2006000278A - Glicosilación en la región variable - Google Patents

Glicosilación en la región variable

Info

Publication number
DOP2006000278A
DOP2006000278A DO2006000278A DO2006000278A DOP2006000278A DO P2006000278 A DOP2006000278 A DO P2006000278A DO 2006000278 A DO2006000278 A DO 2006000278A DO 2006000278 A DO2006000278 A DO 2006000278A DO P2006000278 A DOP2006000278 A DO P2006000278A
Authority
DO
Dominican Republic
Prior art keywords
glycosilation
variable region
variable
region
Prior art date
Application number
DO2006000278A
Other languages
English (en)
Inventor
Hansruedi Loetscher
Walter Huber
Diana Schuhbauer
Karl Weyer
Manfred Brockhaus
Bernd Bohrmann
Hans Koll
Andreas Schaubmar
Kurt Lang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of DOP2006000278A publication Critical patent/DOP2006000278A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
DO2006000278A 2005-12-12 2006-12-11 Glicosilación en la región variable DOP2006000278A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05027090 2005-12-12

Publications (1)

Publication Number Publication Date
DOP2006000278A true DOP2006000278A (es) 2007-07-15

Family

ID=37745986

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2006000278A DOP2006000278A (es) 2005-12-12 2006-12-11 Glicosilación en la región variable

Country Status (34)

Country Link
US (2) US8906370B2 (es)
EP (2) EP1960428B1 (es)
JP (1) JP5145241B2 (es)
KR (2) KR101401159B1 (es)
CN (2) CN101351476B (es)
AR (1) AR057233A1 (es)
AT (1) ATE517923T1 (es)
AU (1) AU2006326301B2 (es)
BR (1) BRPI0619605B8 (es)
CA (1) CA2632828C (es)
CR (1) CR10000A (es)
CY (1) CY1114783T1 (es)
DK (1) DK1960428T3 (es)
DO (1) DOP2006000278A (es)
EC (1) ECSP088524A (es)
ES (1) ES2368591T3 (es)
HK (2) HK1130066A1 (es)
IL (1) IL191004A (es)
JO (1) JO2824B1 (es)
MA (1) MA30038B1 (es)
MY (1) MY155286A (es)
NO (1) NO346105B1 (es)
NZ (1) NZ568241A (es)
PE (3) PE20071002A1 (es)
PL (1) PL1960428T3 (es)
PT (1) PT1960428E (es)
RS (1) RS52004B (es)
RU (1) RU2438706C2 (es)
SI (1) SI1960428T1 (es)
TW (1) TWI382990B (es)
UA (1) UA99097C2 (es)
UY (1) UY30003A1 (es)
WO (1) WO2007068429A1 (es)
ZA (1) ZA200805038B (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
KR101906161B1 (ko) 2005-11-30 2018-10-11 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
AR057233A1 (es) * 2005-12-12 2007-11-21 Hoffmann La Roche Glicosilacion en la region variable
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
CN101553504A (zh) * 2006-12-11 2009-10-07 豪夫迈·罗氏有限公司 Aβ抗体胃肠外制剂
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
BRPI0813963A2 (pt) 2007-06-29 2015-01-06 Hoffmann La Roche Mutante de cadeia pesada que leva a uma melhor produção de imunoglobulina
EP2527367A1 (en) * 2007-08-20 2012-11-28 Glaxo Group Limited Production method
CA2701793C (en) 2007-10-05 2017-04-25 Genentech, Inc. Use of anti-amyloid beta antibody in ocular diseases
EP2234600B1 (en) * 2007-12-21 2014-08-20 F. Hoffmann-La Roche AG Antibody formulation
ES2458541T3 (es) * 2008-05-02 2014-05-06 Seattle Genetics, Inc. Métodos y composiciones para elaborar anticuerpos y derivados de anticuerpos con fucosilación del núcleo reducida
US20120282654A1 (en) * 2009-04-29 2012-11-08 Schering Corporation Antibody purification
EP2519537A4 (en) * 2009-12-29 2013-07-10 Reddys Lab Ltd Dr CLEANING PROTEINS
KR20130010114A (ko) 2010-03-03 2013-01-25 베링거 인겔하임 인터내셔날 게엠베하 바이파라토픽 ａ-베타 결합 폴리펩타이드
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
WO2012016173A2 (en) 2010-07-30 2012-02-02 Ac Immune S.A. Safe and functional humanized antibodies
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US20140302532A1 (en) 2011-04-12 2014-10-09 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury
SG11201401360XA (en) * 2011-10-25 2014-05-29 Onclave Therapeutics Ltd Antibody formulations and methods
WO2013081946A1 (en) * 2011-12-02 2013-06-06 Plaxgen, Inc. Plaque array method and compositions for forming and detecting plaques
RS54644B1 (en) 2012-03-08 2016-08-31 F. Hoffmann-La Roche Ag ABET ANTIBODY FORMULATION
CA2879496C (en) * 2012-08-29 2024-01-09 F. Hoffmann-La Roche Ag Blood brain barrier shuttle
CN102998454A (zh) * 2012-12-11 2013-03-27 华中师范大学 一种检测生物体内邻苯二甲酸二丁酯相对含量的方法
US9587022B2 (en) 2012-12-18 2017-03-07 The Rockefeller University Glycan-modified anti-CD4 antibody with improved HIV-1 neutralizing activity
TWI630215B (zh) * 2012-12-18 2018-07-21 美國洛克菲勒大學 用於ｈｉｖ預防及治療的醣修飾抗ｃｄ４抗體
AR094780A1 (es) 2013-02-13 2015-08-26 Laboratoire Français Du Fractionnement Et Des Biotechnologies ANTICUERPOS ANTI-TNF-a ALTAMENTE GALACTOSILADOS Y SUS USOS
JP6169885B2 (ja) 2013-05-07 2017-07-26 株式会社日立製作所 精製装置及び精製方法
WO2015038884A2 (en) 2013-09-13 2015-03-19 Genentech, Inc. Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products
NZ756750A (en) 2013-09-13 2022-05-27 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
WO2015075942A1 (ja) 2013-11-22 2015-05-28 国立大学法人 東京大学 薬剤送達用のキャリア、コンジュゲートおよびこれらを含んでなる組成物並びにこれらの投与方法
JP6744856B2 (ja) 2014-04-08 2020-08-19 プロセナ・バイオサイエンシズ・リミテッド α−シヌクレインを認識する抗体を含む血液脳関門シャトル
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
DK3313879T3 (da) 2015-06-24 2022-03-14 Hoffmann La Roche Anti-transferrinreceptor-antistoffer med tilpasset affinitet
WO2017032686A1 (en) * 2015-08-21 2017-03-02 F. Hoffmann-La Roche Ag Method for the reduction of host cell proteins in affinity chromatography
KR20180054864A (ko) 2015-10-02 2018-05-24 에프. 호프만-라 로슈 아게 이중특이성 항-인간 cd20/인간 트랜스페린 수용체 항체 및 사용 방법
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
HUE057085T2 (hu) * 2015-10-16 2022-04-28 Hoffmann La Roche Egy rendszer mûködtetésére szolgáló eljárás és egy rendszer
WO2017079833A1 (en) 2015-11-09 2017-05-18 The University Of British Columbia Epitopes in amyloid beta mid-region and conformationally-selective antibodies thereto
EP3374379A4 (en) 2015-11-09 2019-05-15 The University Of British Columbia N-TERMINAL EPITOPES IN BETA-AMYLOID AND CONFORMATIONALLY SELECTIVE ANTIBODIES THEREOF
US10759837B2 (en) 2015-11-09 2020-09-01 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
US10792477B2 (en) * 2016-02-08 2020-10-06 Orbusneich Medical Pte. Ltd. Drug eluting balloon
WO2017153848A1 (en) * 2016-03-10 2017-09-14 Genomic Vision Method of curvilinear signal detection and analysis and associated platform
WO2017189959A1 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
TWI735600B (zh) 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
AU2018277333B2 (en) * 2017-05-30 2021-09-16 Morinaga Milk Industry Co., Ltd. Composition for improving brain function
EP3574020B1 (en) 2017-07-18 2024-05-15 The University of British Columbia Antibodies to amyloid beta
CN108048477A (zh) * 2017-12-15 2018-05-18 南京理工大学 基于大肠杆菌表达***的制备多肽的方法
EP3778875A1 (en) 2019-08-14 2021-02-17 MaxiVax SA Immortalized myoblast cell lines and uses thereof
JP2023535024A (ja) 2020-07-23 2023-08-15 オター プロシーナ リミテッド 抗ａベータ抗体
EP4244248A1 (en) 2020-11-16 2023-09-20 F. Hoffmann-La Roche AG Fab high mannose glycoforms
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
CN114591429B (zh) * 2022-05-07 2022-08-09 北京第一生物化学药业有限公司 结合β-淀粉样蛋白的抗体及其用途

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5811310A (en) 1986-09-30 1998-09-22 Albert Einstein College Of Medicine Of Yeshiva Univ. The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
CA1339014C (en) 1987-10-08 1997-03-25 Ronald E. Majocha Antibodies to a4 amyloid peptide
JP2780507B2 (ja) * 1991-03-29 1998-07-30 松下電器産業株式会社 内燃機関用フィルタ再生装置
US5955317A (en) * 1993-01-25 1999-09-21 Takeda Chemical Industries, Ltd. Antibodies to β-amyloids or their derivatives and use thereof
EP1308461A3 (en) 1993-01-25 2004-02-11 Takeda Chemical Industries, Ltd. Antibodies to beta-amyloids or their derivatives and use thereof
US5443953A (en) * 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
GB9416007D0 (en) * 1994-08-08 1994-09-28 Erba Carlo Spa Anthracyclinone derivatives
US5688651A (en) * 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
EP0838033A1 (en) * 1995-06-06 1998-04-29 Stemcell Therapeutics L.L.C. GLYCOPROTEIN gp105 ON BL3 HEMATOPOIETIC STEM CELLS
PT859841E (pt) 1995-08-18 2002-11-29 Morphosys Ag Bibliotecas de proteinas/ (poli) peptidos
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
NZ514414A (en) * 1999-03-04 2004-02-27 Praecis Pharm Inc Modulators of beta-amyloid peptide aggregation comprising D-amino acids
AU780474B2 (en) 1999-06-16 2005-03-24 Boston Biomedical Research Institute Incorporated Immunological control of beta-amyloid levels in vivo
AU6722300A (en) 1999-08-31 2001-03-26 Ramot University Authority For Applied Research And Industrial Development Ltd. Peptides and substances, methods and devices using same for diagnosing and treating neurodegenerative disorders
NZ540564A (en) 1999-11-29 2007-04-27 Neurochem Int Ltd Vaccine for the prevention and treatment of Alzheimer's and amyloid related diseases
US20020094335A1 (en) 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
EP1125905A1 (en) 2000-02-16 2001-08-22 Pepscan Systems B.V. Segment synthesis
PL210157B1 (pl) 2000-02-24 2011-12-30 Lilly Co Eli Humanizowane przeciwciało lub jego fragment, kwas polinukleinowy, wektor ekspresyjny do ekspresji przeciwciała lub jego fragmentu, komórka transfekowana wektorem ekspresyjnym, kompozycja farmaceutyczna i zastosowanie humanizowanego przeciwciała lub jego fragmentu do leczenia choroby Alzheimera
CA2313828A1 (en) 2000-08-01 2002-02-01 Institut De Recherches Cliniques De Montreal/Ircm Post-translational processing of .beta.-secretase (bace): the pro-and transmembrane/cytosolic domains affect its cellular activity and amyloid a.beta. production
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
EP1379283B1 (en) 2000-12-19 2008-02-13 Palatin Technologies, Inc. Identification of target-specific folding sites in peptides and proteins
ATE420114T1 (de) 2001-04-30 2009-01-15 Lilly Co Eli Humanisierte antikörper die das beta-amyloid peptid erkennen& x9;
AU2002257162A1 (en) 2001-04-30 2002-11-11 Eli Lilly And Company Humanized antibodies
CA2451998A1 (en) * 2001-08-17 2003-02-27 Eli Lilly And Company Anti-a.beta. antibodies
EP1944040B1 (en) * 2001-08-17 2012-08-01 Washington University Assay method for Alzheimer's disease
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
PL377769A1 (pl) 2002-10-09 2006-02-20 Rinat Neuroscience Corp. Sposób leczenia choroby Alzheimera z zastosowaniem przeciwciał skierowanych przeciw peptydowi beta amyloidu i ich kompozycje
DE10303974A1 (de) * 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
AR057233A1 (es) * 2005-12-12 2007-11-21 Hoffmann La Roche Glicosilacion en la region variable
CN101553504A (zh) * 2006-12-11 2009-10-07 豪夫迈·罗氏有限公司 Aβ抗体胃肠外制剂

Also Published As

Publication number Publication date
RU2008128138A (ru) 2010-01-20
US20150165022A1 (en) 2015-06-18
ECSP088524A (es) 2008-07-30
BRPI0619605A2 (pt) 2011-10-11
CN101351476A (zh) 2009-01-21
NO346105B1 (no) 2022-02-21
KR20080077132A (ko) 2008-08-21
BRPI0619605A8 (pt) 2019-01-15
CA2632828A1 (en) 2007-06-21
TW200736273A (en) 2007-10-01
EP1960428A1 (en) 2008-08-27
ATE517923T1 (de) 2011-08-15
EP1960428B1 (en) 2011-07-27
JO2824B1 (en) 2014-09-15
PE20100748A1 (es) 2010-11-12
MY155286A (en) 2015-09-30
TWI382990B (zh) 2013-01-21
UA99097C2 (ru) 2012-07-25
CN102659943A (zh) 2012-09-12
KR101401159B1 (ko) 2014-05-29
KR20120089483A (ko) 2012-08-10
PE20071002A1 (es) 2007-11-19
CN101351476B (zh) 2013-04-03
SI1960428T1 (sl) 2011-10-28
DK1960428T3 (da) 2011-08-22
BRPI0619605B1 (pt) 2019-08-13
NZ568241A (en) 2011-08-26
US9272031B2 (en) 2016-03-01
CY1114783T1 (el) 2016-12-14
RS52004B (en) 2012-04-30
JP5145241B2 (ja) 2013-02-13
HK1130066A1 (en) 2009-12-18
AU2006326301B2 (en) 2011-04-21
PT1960428E (pt) 2011-10-07
AU2006326301A1 (en) 2007-06-21
IL191004A (en) 2013-08-29
PE20100684A1 (es) 2010-10-04
PL1960428T3 (pl) 2012-02-29
HK1176075A1 (en) 2013-07-19
MA30038B1 (fr) 2008-12-01
AR057233A1 (es) 2007-11-21
ZA200805038B (en) 2009-06-24
CN102659943B (zh) 2015-07-01
JP2009520691A (ja) 2009-05-28
EP2377886A1 (en) 2011-10-19
UY30003A1 (es) 2007-08-31
WO2007068429A1 (en) 2007-06-21
US8906370B2 (en) 2014-12-09
CR10000A (es) 2008-07-29
RU2438706C2 (ru) 2012-01-10
NO20082874L (no) 2008-08-28
US20090252724A1 (en) 2009-10-08
ES2368591T3 (es) 2011-11-18
CA2632828C (en) 2012-07-10
BRPI0619605B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
DOP2006000278A (es) Glicosilación en la región variable
DK2194043T3 (da) Fremgangsmåder
ATE408603T1 (de) Pyrazolylcarboxanilide
CR9974A (es) Gavión
DK1683933T3 (da) Betjeningsgreb
DE602006012066D1 (de) Daraus
DE602005022364D1 (de) Selbstbräunendes kosmetikum
ATE549324T1 (de) Tetrahydrobenzoxazine
DE602006021721D1 (de) Nadellager
ATE485368T1 (de) Hiv - impfung
DE102005052834B8 (de) Punktschweißklebverbindung
FI6695U1 (fi) Termotela
DK1960510T3 (da) Ammoniakspecifik 5'-xmp-aminasemutant
NO20052429D0 (no) Konstrastmidler
DE602005007329D1 (de) Schere
DK1931573T3 (da) Lukke
AT501968A3 (de) Mitführhilfe
FI20050653A0 (fi) Suodatinmateriaali
FI20045499A0 (fi) Järjestely oskillointilaitteessa
FI20051214A0 (fi) Kello-laskin
UY3545Q (es) Configuración aplicada en licuadora
ITLE20050017A1 (it) Il paravolatili
ITRE20050006U1 (it) Il fermacassero
FI20055146A0 (fi) Virtauksenjakaja
FIU20050035U0 (fi) Pikalukitsin